RCM
SVA

Rotella Capital Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Rotella Capital Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-26,429
Closed -$104K – 212
2013
Q2 		$104K Buy
+26,429
New +$98.3K 0.33% 44

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Rotella Capital Management's SVA Position: Q3 2013 in Review

Rotella Capital Management sold out of Sinovac Biotech, Ltd (SVA) in Q3 2013, closing a stake of 26,429 shares — an estimated $104K sold.

Rotella Capital Management first reported a position in SVA in Q2 2013 and held it in 1 quarter. The position peaked at $104K in Q2 2013. 35 funds tracked by Wall St. Rank hold SVA as of Q3 2013.

  • Rotella Capital Management reported no remaining Sinovac Biotech, Ltd position as of Q3 2013 after selling out during the quarter.
  • Rotella Capital Management sold 26,429 Sinovac Biotech, Ltd shares in Q3 2013, an estimated $104K.
  • Rotella Capital Management first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 1 quarter.
  • Rotella Capital Management's Sinovac Biotech, Ltd position peaked at $104K in Q2 2013.
  • 35 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2013.

Based on Rotella Capital Management's 13F filing for Q3 2013, filed 18 Nov 2013.